Zacks Research Upgrades XOMA Royalty (NASDAQ:XOMA) to “Hold”

XOMA Royalty (NASDAQ:XOMA) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research analysts have also recently issued reports on XOMA. Wall Street Zen cut XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright decreased their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Leerink Partners dropped their price objective on XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, December 11th. Stifel Nicolaus set a $50.00 target price on shares of XOMA Royalty in a report on Friday, December 12th. Finally, UBS Group set a $76.00 price target on shares of XOMA Royalty in a report on Tuesday, December 9th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, XOMA Royalty has an average rating of “Moderate Buy” and an average target price of $60.60.

XOMA Royalty Trading Down 3.2%

Shares of XOMA opened at $22.89 on Monday. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $39.92. The stock has a market cap of $283.38 million, a PE ratio of 30.93 and a beta of 0.86. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The business’s 50-day moving average price is $26.87 and its 200-day moving average price is $31.20.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The firm had revenue of $9.35 million for the quarter, compared to the consensus estimate of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. On average, equities analysts forecast that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Insider Activity at XOMA Royalty

In related news, CEO Owen Hughes bought 100,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was purchased at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the transaction, the chief executive officer owned 102,000 shares in the company, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue bought a new position in XOMA Royalty in the 4th quarter worth about $27,000. Russell Investments Group Ltd. raised its holdings in XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of XOMA Royalty during the second quarter valued at approximately $116,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.